Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals — Investor Presentation (December 2022)

42 slides from Zynerba Pharmaceuticals's investor presentation, Dec 5, 2022

  1. Slide 1: Advancing Science. Improving Connections.

    © 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. NASDAQ ZYNE Advancing Science. Improving Connections. December 2022

  2. Slide 2: Forward-Looking Statements

    Forward - Looking Statements The statements in this presentation may include forward - looking statements within the meaning of the private securities litigati on reform act of 1995. These statements, among other things relate to the future operations, opportunities or financial performance of Zyn e

  3. Slide 3: A different and exciting approach to Cannabidiol

    A different and exciting approach to Cannabidiol

  4. Slide 4: An Orphan-Focused Neuropsychiatric, Biopharmaceutical Company

    An Orphan - Focused Neuropsychiatric, Biopharmaceutical Company Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 4 Permeation - enhanced Patent - protected through 2040 Pharmaceutically manufactured; THC free FIRST AND ONLY TRANSDERMAL CANNABIDIOL GEL One Phase 3 clinical program

  5. Slide 5: Benefits of Our Approach to Cannabidiol

    Benefits of Our Approach to Cannabidiol Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 5 FDA regulated Consistency of production Purity of ingredients No THC – not a scheduled drug by U.S. DEA Scalable production process PHARMACEUTICAL MANUFACTURING PHARMACEUTICAL DISPENSARY Eas

  6. Slide 6: Clinical Development Programs

    Clinical Development Programs Fragile X Syndrome FXS 22q Deletion Syndrome 22q Autism Spectrum Disorder ASD

  7. Slide 7: Overlap of Symptoms Across Conditions

    Overlap of Symptoms Across Conditions Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 7 Anxiety Seeks Isolation Social Avoidance Lack of Interaction Attention Deficits Irritability FXS 22q ASD December 2022

  8. Slide 8: Focused Clinical Pipeline

    Fragile X Syndrome (FXS) Focused Clinical Pipeline Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 8 Preclinical Phase 1 Phase 2 Pivotal Market 22q Deletion Syndrome (22q) Autism Spectrum Disorder (ASD) Regulatory Filing U.S. Orphan Drug and Fast Track designations; EU Orphan Dru

  9. Slide 9: Well-Tolerated Safety Profile

    • Majority of treatment - emergent AEs (TEAEs) were mild or moderate • Most common Zygel - related • No clinically significant changes in vital signs or ECGs • No Zygel - related clinically significant changes in laboratory values, including liver function tests Zynerba Pharmaceuticals | Advancing S

  10. Slide 10: Fragile X Syndrome

    [ Fragile X Syndrome bane aa

  11. Slide 11: What is Fragile X Syndrome (FXS)?

    ~78K U.S. PATIENTS What is Fragile X Syndrome (FXS)? Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 11 • Leading known cause of inherited intellectual disability and autism spectrum disorder • Mutation of the FMR1 gene causes endocannabinoid system (ECS) dysregulation • Easily i

  12. Slide 12: Poised for Success in FXS

    Poised for Success in FXS Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 12 Largest clinical trial ever conducted in children with FXS Extensive safety database Patients on drug for up to five years Statistically significant outcomes in children with complete methylation Lessons

  13. Slide 13: Role of FMR1 Methylation in FXS

    Role of FMR1 Methylation in FXS Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 13 • FMR1 gene codes for production of FMRP* which is vital to synapse development • Methylation of the FMR1 gene plays a role in determining gene function • When methylation of the FMR1 gene silences

  14. Slide 14: CONNECT-FX Trial Key Learning: Results with complete methylation

    CONNECT - FX Trial Key Learning: Results with complete methylation of FMR1 gene Consistent Improvements Observed with Zygel vs. Placebo in Patients with Complete Methylation Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 14 PRIMARY ENDPOINT CAREGIVER REPORTED BEHAVIOR CHANGE CLI

  15. Slide 15: Clinically Meaningful Improvement in Patients with Complete Methylation

    Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 15 Clinically Meaningful Improvement a Achieved and Maintained in Patients with Complete Methylation b 0 10 20 30 40 50 60 70 80 90 100 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Cumulative Percentage of Patients Month Zygel (n=47) Pl

  16. Slide 16: CONNECT-FX Data Published in the Journal of Neurodevelopmental Disorders

    CONNECT - FX Data Published in the Journal of Neurodevelopmental Disorders Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 16 December 2022 • “…ZYN002 was well tolerated in patients with FXS and demonstrated evidence of efficacy with a favorable benefit risk relationship in patie

  17. Slide 17: Design Optimized from CONNECT-FX Trial

    Design Optimized from CONNECT - FX Trial Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 17 More patient and family friendly Extending trial to 18 - weeks Increased dosing option for individuals >50 kg Successful completion of Phase 3 pivotal trial expected to satisfy requirement

  18. Slide 18: Confirmatory Pivotal Trial Design

    Confirmatory Pivotal Trial Design Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 18 Double - Blind, Placebo - Controlled Study: Initiated 18 weeks Zygel (n~100; 80*) 250 mg daily (≤30kg) 500 mg daily (>30kg) 750 mg daily (>50kg) (weight - based dose) Placebo (n~100; 80*) Mirrors

  19. Slide 19: Trial Objectives

    Trial Objectives Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 19 Change from baseline to end of treatment in ABC - C FXS Social Avoidance subscale in patients who have complete (100%) methylation of their FMR1 gene • Change from baseline to end of treatment in: • ABC - C FXS I

  20. Slide 20: Next Steps in FXS

    Next Steps in FXS Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 20 Continued RECONNECT pivotal trial enrollment Topline results expected in 2H 2023 November 2022

  21. Slide 21: 22q11.2 Deletion Syndrome (22q)

    22q11.2 Deletion Syndrome (22q) Image courtesy Positive Exposure © 2016 Positive Exposure. All rights reserved. www.PositiveExposure.org . Eliza, living with 22q11.2 deletion syndrome

  22. Slide 22: What is 22q11.2 Deletion Syndrome (22q)?

    What is 22q11.2 Deletion Syndrome (22q)? Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 22 • Rare disorder and second most common genetic disorder, behind Down yndrome • Midline condition with abnormalities affecting palate, face, heart and other organs; surgically corrected in

  23. Slide 23: Rationale for Zygel in 22q

    U.S. & EU ORPHAN DRUG DESIGNATION GRANTED FOR TREATMENT OF 22q Rationale for Zygel in 22q Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 23 • Overlapping symptoms with FXS and ASD • Associated with increased anxiety, irritability, social withdrawal and social interaction problem

  24. Slide 24: INSPIRE Phase 2 Trial Design

    INSPIRE Phase 2 Trial Design Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 24 Period 1: Completed 14 weeks Zygel (n = 20) 250 mg daily (≤35kg) 500 mg daily (>35kg) (weight - based dose) Period 2: Completed 24 weeks Efficacy assessments include: (week 14 vs baseline) • Anxiety,

  25. Slide 25: INSPIRE Trial Efficacy and Safety Results

    • Statistically significant improvements at 14 weeks and 38 weeks of treatment compared to baseline for multiple efficacy assessments: • The total score and all five subscales of the Anxiety, Depression and Mood Scale (ADAMS) • All five subscales of the Aberrant Behavior Checklist – Community (ABC -

  26. Slide 26: Significant Improvement in Anxiety as Measured by the PARS-R

    26 Efficacy: Significant Improvement in Anxiety as Measured by the PARS - R 14.7 8.5 0 2 4 6 8 10 12 14 16 PARS - R score 40.6% ( P =.0005) Baseline (n=15) Week 14 (n=15) 15.3 7.4 0 2 4 6 8 10 12 14 16 PARS - R score 49.4% ( P =.0001) Baseline (n=11) Week 38 (n=11) The efficacy analysis for Period 1

  27. Slide 27: Significant Improvements in ADAMS Total and Subscale Scores

    27 Efficacy: Significant Improvements in ADAMS Total and Subscale Scores Mean Scores and Percentage Improvement Period 1 14 weeks 36.1 10.4 7.6 8.7 3.0 7.6 17.7 5.1 3.4 4.3 1.1 4.4 0 5 10 15 20 25 30 35 40 Baseline (n=16) Week 14 (n=16) ADAMS total and subscale scores 45.3% ( P =.0005) 43.6% ( P= .0

  28. Slide 28: Significant Improvements in All ABC-C Subscale Scores

    28 Efficacy: Significant Improvements in All ABC - C Subscale Scores ABC - C subscale score 36.3% ( P =.0055) 18.3% ( P= .0166) 52.1% ( P= .0155) 16.5% ( P= .0091) 27.6% ( P= .011) 41.6% ( P =.0087) 63.3% ( P= .0028) 73.3% ( P= .0270) 48.1% ( P= .0232) 59.4% ( P= .0174) ABC - C subscale score Period

  29. Slide 29: Next Steps in 22q

    Next Steps in 22q Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 29 Discuss regulatory pathway with FDA Initiate Phase 3 program after RECONNECT topline results December 2022

  30. Slide 30: Autism Spectrum Disorder

    Autism Spectrum Disorder

  31. Slide 31: Rationale for Zygel in Autism Spectrum Disorder (ASD)

    Rationale for Zygel in Autism Spectrum Disorder (ASD) Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 31 • Results from FXS trials suggested spectrum of activity against behaviors also seen in ASD: irritability, social avoidance and anxiety • Studies suggested ASD is linked to di

  32. Slide 32: BRIGHT Open-label Phase 2 Trial Design

    BRIGHT Open - label Phase 2 Trial Design Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 32 Period 1 14 weeks 6 Zygel (n = 37) 250 mg daily (≤35kg) 500 mg daily (>35kg) (weight - based dose) Period 2 24 weeks 18 Patients with ≥ 35% improvement in Irritability at week 14 continued

  33. Slide 33: BRIGHT Phase 2 Trial Results: Period 1

    BRIGHT Phase 2 Trial Results: Period 1 Statistically Significant Results at Week 14 Compared to Baseline (Completers in Efficacy Population n=28 † ) Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 33 † n=26 for ABC - C inappropriate speech; *Statistically significant; Full data a

  34. Slide 34: BRIGHT Period 2 Results: Improvements Sustained through Week 38

    50% ( P< 0.0001 ) 61% ( P <0.0001) 60% ( P <0.0001) 53% ( P <0.0001) 56% ( P <0.0001) 0 5 10 15 20 25 30 35 40 Irritability Inappropriate Speech Stereotypy Social Withdrawal Hyperactivity ABC - C Subscale Score Mean Scores Baseline Week 14 Week 38 BRIGHT Period 2 Results: Statistically Significant I

  35. Slide 35: ASD Current Status

    ASD Current Status Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 35 Investigational New Drug (IND) submitted in 2022 and given clearance to proceed by FDA ASD is now third in priority and initiation of Phase 3 program is deferred at this time December 2022

  36. Slide 36: Positioned for Success

    Positioned for Success

  37. Slide 37: Leadership

    Leadership Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 37 Armando Anido Chairman of the Board and CEO Terri B. Sebree President Jim Fickenscher CFO and VP, Corporate Development Paul Kirsch VP, Regulatory Affairs and Quality Assurance Joe Apostolico VP, Human Resources Terry

  38. Slide 38: Financial Strength

    Financial Strength Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 38 CASH AND CASH EQUIVALENTS $55.9M as of September 30, 2022; expected to be sufficient to fund operations and capital requirements into Q1 2024 BALANCE SHEET CLEAN No debt, 47.1M shares outstanding (as of Novembe

  39. Slide 39: A Year of Clinical Progress Ahead

    A Year of Clinical Progress Ahead Zynerba Pharmaceuticals | Advancing Science. Improving Connections. 39 Pivotal trial results expected in 2H 2023 Finalize regulatory pathway with FDA; Initiate Phase 3 after RECONNECT topline results IND submitted in 2022 and given clearance to proceed by FDA; initi

  40. Slide 40: Zynerba Vision for Future Growth

    • Launch Zygel for FXS into a $1.9B+ U.S. market opportunity • Establish a fully integrated organization with U.S. commercial presence • Preparing for EU approval in FXS • Advance 22q and ASD Ph3 programs towards completion • Leader in transdermal cannabidiol delivery • Late - stage clinical company

  41. Slide 41: A different and exciting approach to Cannabidiol

    A different and exciting approach to Cannabidiol

  42. Slide 42: Thank you!

    © 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. NASDAQ ZYNE Thank you!

Zynerba Pharmaceuticals — Investor Presentation (December 2022) on 6ix